《大行報告》大和降舜宇(02382.HK)目標價至60元 今年有望實現強勁增長
大和發表研報指,受累手機鏡頭模組(HCM)定價壓力大過預期,舜宇光學(02382.HK)去年下半年利潤率遜於預期,下半年純利則符合預期,較上半年增長52%。大和指,管理層對今年產品平均售價及利潤率前景的積極看法,支持該行認爲舜宇已走過低谷的看法,今明兩年有望迎來強勁盈利復甦。
該行相信,智能手機等設備的規格升級潮再現,憧憬舜宇今年可實現強勁增長,預測今明兩年盈利可按年增長59%至65%,毛利率則由去年的14.5%回升至介乎16%至17.7%。
該行將今明兩年每股盈利預測下調3%至8%,以反映更審慎的利潤率預測,重申「買入」評級,目標價由70元降至60元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.